Texas Uterine Cancer LawyerA growing number of lawsuits are being filed by women who were diagnosed with uterine cancer after doctors used a laparoscopic power morcellator during their hysterectomy. If you were not aware of the risk of cancer before your hysterectomy, you are not alone.

Need a Texas Uterine Cancer Lawyer? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was injured by a morcellator, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit in Texas.

Uterine Cancer and Morcellators

Every year, more than 600,000 women in the United States has surgery to remove the uterus (hysterectomy). The vast majority of hysterectomies are used to treat uterine fibroids, a benign condition with a lifetime risk of more than 70%, and many of these procedures are elective.

In recent decades, the use of minimally-invasive laparoscopic techniques has surged — especially robot-assisted procedures. One of the most popular tools is the laparoscopic power morcellator, a device that grinds up fibroids into tiny pieces of tissue.

The problem is that some women who think they have fibroids actually has cancer. When a morcellator grinds up cancerous tissue, it often leaves behind cancerous cells. This can essentially “seed” a woman’s pelvis and abdomen with uterine cancer, greatly reducing her chances of long-term survival.

FDA Warning

April 2014 — In a Safety Communication, the U.S. Food and Drug Administration (FDA) is advising against the use of laparoscopic power morcellators for the removal of the uterus (hysterectomy) due to the risk of spreading undiagnosed uterine cancer.

The FDA warned:

“The FDA has determined that approximately 1 in 350 women who are undergoing hysterectomy or myomectomy for fibroids have an unsuspected type of uterine cancer called uterine sarcoma. If laparoscopic power morcellation is performed in these women, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival.”

What is Uterine Cancer?

Uterine cancer occurs when cells begin growing uncontrollably inside the uterus. The most common type is endometrial cancer, which grows in the lining of the uterus (endometrium). Uterine cancer is the fourth most common cancer. In 2010, about 45,000 women were diagnosed with uterine cancer and 8,400 died from it. About 1,600 of these women were diagnosed with uterine sarcoma.

Uterine Fibroids and Cancer

Every year, thousands of women are diagnosed with benign (non-cancerous) tumors in the uterus, such as a fibroids (leiomyomas). Most women develop fibroids at some point in their life. They are one of the most common reasons for a hysterectomy.

Unfortunately, in some cases, fibroids are actually uterine sarcoma. This is a disease in which malignant (cancerous) cells grow in the uterus. Uterine sarcoma includes leiomyosarcoma (LMS), a highly-aggressive type of cancer. It is impossible to tell whether a fibroid is actually uterine sarcoma until after the tissue is removed from a woman’s body.

Symptoms

Gynecological cancer symptoms include:

  • Abnormal vaginal bleeding or discharge
  • Pelvic pain or pressure
  • Abdominal or back pain
  • Bloating
  • Changes in bathroom habits
  • Itching or burning of the vulva
  • Changes in vulva color or skin (rash, sores, or warts)

Need a Uterine Cancer Lawyer in Texas?

Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.

Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”

The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact our Texas lawyers for a free lawsuit review.